Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. by Itoh, K. et al.
British Joumal ofCancer(1997) 76(1), 107-113
© 1997 Cancer Research Campaign
Patients in phase I trials of anti-cancer agents in Japan:
motivation, comprehension and expectations
K Itoh, Y Sasaki, H Fuji!, T Ohtsu, H Wakita, T Igarashi and K Abe
Division of Oncology/Hematology, Department of Medicine, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277, Japan
Summary We attempted to characterize the motivation, comprehension and expectations of patients who had given informed consent to
participate in phase I trials of anti-cancer agents at the National Cancer Center of Japan. Thirty-three patients were given a simple multiple-
choice questionnaire and asked to return it at a later date. The completed survey was returned by 32 patients. The patients were surveyed
before they had received any investigational phase agents. Nineteen per cent of patients were motivated to participate in the phase trials
bythe possibility oftherapeutic benefit, 9% because participation seemed a betterchoice than no treatment and only 6% foraltruistic reasons.
Most patients comprehended the major features of a phase trial, namely its investigational nature, the unknown effects of the agent
investigated and the unclear benefit to the patients themselves. Fifty-nine per cent of the patients anticipated that they might suffer severe or
life-threatening side-effects if they participated in the phase trial, and 43% were able to indicate accurately the purpose of the phase trial as
a dose determination study. Although only a minority of the patients indicated that their motivation to participate was possible treatment
benefit to themselves, when answering questions regarding expectations, more than half indicated that there might be personal benefits of
varying degrees by participation.
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The primary goals ofphase I clinical trials foranti-cancer agents are
to determine toxicity, maximum tolerated dose and recommended
dose forthephase II study, as well as pharmacological evaluation of
the new drug (Simon, 1993). Preliminary evaluation ofanti-tumour
activity may also be included in phase I clinical trials.
A phase I clinical trial is the initial trial in human subjects of a
new agent. Although healthy volunteers are appropriate candidates
for phase I trials, this generalization does not apply to phase I trials
of anti-cancer agents because of the side-effects and narrow thera-
peutic window. Anti-cancer agents inphase I trials should always be
administered to patients with incurable cancer with the expectation
of some therapeutic benefit. Accordingly, it is not surprising that
toxicity and possible benefits of such agents are often unknown,
even when there is promising preclinical data. In addition, in phase
I trials, early cohorts of patients are treated at very low and some-
times ineffective dosages. The overall response rate in phase I trials
is low (Estey et al, 1986; Decoster et al, 1990; Von HoffandTurner,
1991; Penta etal, 1992; Itohetal, 1994). Furthermore, physicians as
investigators conducting phase I trials of anti-cancer agents must
always be vigilant in safeguarding the patients' best interests when
confronted with ethical issues (e.g. benefit vs toxicity), and, more-
over, obtaining truly informed consent is difficult (Lipsett, 1982;
Ratain et al, 1993; Emanuel, 1995).
Although almost all investigators and institutional review
boards agree as to the importance of informed consent (Kodish et
al, 1992) and the guiding concept in ethical clinical research is
informed consent, which is meant to guarantee the voluntary
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nature ofparticipation in clinical trials, there have been only a few
reports from the viewpoint of the patients in phase I clinical trials
of anti-cancer agents (Rodenhuis et al, 1984; Tomamichel et al,
1995; Daugherty et al, 1995). Furthermore, it is ofinterest to learn
whether the patients' perception of these studies in Japan differs
from that ofpatients in the United States and Europe. We adminis-
tered a questionnaire to 33 consecutive patients who had given
informed consent to participate in a phase I trial of anti-cancer
agents at the National CancerCenterHospital East in an attempt to
characterize their motivation, comprehension and expectations.
PATIENTS AND METHODS
The subjects were 33 patients with advanced or metastatic cancer
who had given informed consent consecutively to participate in
one of three phase I trials of anti-cancer agents [NB506 (Banyu
Pharmaceutical), SZS-PSC833 in combination with doxorubicin
(Sandoz Pharmaceuticals), JM216 (Bristol-Myers Squibb)]
conducted at the National Cancer CenterHospital Eastbetween 23
June 1994 and 21 September 1995. Patients were asked if they
would agree to participate in a survey by completing a question-
naire. Once verbal approval was obtained, a simple multiple-
choice questionnaire was distributed, with assurance of
anonymity, before any treatment with the agents under investiga-
tion was administered but after they received detailed information
concerning the objectives of the trial. In addition to the informa-
tion provided in the consent forms, patients were verbally
informed firstly as to the incurable nature of their cancer, for
which no standard treatment was available, secondly that a phase I
clinical trial is the first trial in human subjects for research
purposes on effectiveness of an anti-cancer agent and, finally, of
the objectives, methods, potential risks and uncertain effects ofthe
trial. In addition, general information about the clinical study was
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Table 1 Demographics of the surveyed patients (n= 32)
Characteristic No. of patients
Gender
Male 15
Female 17
Age (median 58 years)
<49 9
50-59 10
>PO 13
Occupation
None/retired 14
White collar/professional 12
Not described 6
Education
Did not attend high school 5
High school 15
Beyond high school 9
Unknown 3
Malignant tumour
Gastrointestinal tract 9
Breast 7
Head and neck 5
Lung 3
Gynaecourinary 3
Others 5
Prior therapy
None 1
Operation ± radiotherapy 3
Chemotherapy ± radiotherapy 9
Operation + chemotherapy ± radiotherapy 19
provided. The no treatment option that was included in the written
consent form was explained. The information regarding the phase
I trial was standardized in the written consent forms and physi-
cians used this information to reduce variance of the verbal
presentation among the six staffphysicians involved in the study.
The questionnaires were returned by mail or hand delivered to
each physician and were considered as confidential information. A
single physician managed the entire process ofthe distribution and
recovery ofthe survey forms.
All patients who were candidates for phase I trials had a histo-
logically confirmed malignancy for which there was no effective
chemotherapy or which had been demonstrated to be refractory to
standard therapy. Other eligibility criteria in the three phase I trials
were: patient must be older than 20 years; a good performance
status (PS) [PS 0-2 by Eastern Cooperative Oncology Group
(ECOG)]; no radiation therapy or chemotherapy within 4 weeks
before entry into the trials; adequate organ function; no serious
complications; and written informed consent.
The questionnaire study was approved by the Institutional
Review Board and Ethical Committee at the National Cancer
Center in Japan. Statistical analysis was performed using Fisher's
exact probability test in Stat View.
RESULTS
All 33 patients returned the questionnaires, but one patient failed
to complete the survey, leaving 32 completed forms for analysis.
The characteristics of the 32 patients are summarized in Table 1.
Median age was 58 years (range 30-68 years), and 53% were
Table 2 Motivations for participation in the phase trial
n (%)
The major reason for participation in the phase trial isa
Some treatment benefit for myself
No treatment benefit to myself but wish to participate anyway
Family's advice
To help future cancer patients
Better option than no treatment
Advice of doctor
Trust in doctor
If my doctor proposed a phase trial again, would
Participate
Refuse
Don't know
think the phase trial will help future cancer patients
Agree
Disagree
Don't know
6 (19)
20 (63)
0 (0)
2 (6)
3 (9)
7 (22)
9 (28)
19 (73)
1 (4)
6 (23)
28 (90)
0 (0)
3 (10)
aAlthough patients were instructed to select the single most important reason,
some patients selected more than one reason.
Table 3 Patients' decision-making for participation in the phase trial
n (%)
Arriving at the decision to participate in the phase trial was
Easy 19 (63)
Somewhat difficult 7 (23)
Very difficult 4 (13)
made an independent decision 2 (7)
consulted my (include any of the following)
Spouse 24 (80)
Child 17 (57)
Parent 2 (7)
Sibling 4 (13)
Other relative 4 (13)
Friend 5 (17)
Doctor 13 (43)
Nurse 1 (3)
women. Four patients were unable to participate in phase I trials
because neutropenia was detected before registration. All patients
except one had received some previous treatment.
Perception
With regard to patient's perception ofthe lack ofor the failure of a
standard treatment in treating the cancer, 25 patients (86%) under-
stood the concept that an investigational treatment or standard
comfort care should be chosen by the patient after consultation
with the physician ifthere is no standard treatment or if the treat-
ment has failed to treat the cancer.
Motivation
As shown in Table 2, 20 patients (63%) indicated that they did not
expect any benefit but wished to participate anyway. Furthermore,
11 of these 20 patients said that they would participate in another
phase I trial if their doctor suggested it. Three patients (9%) indi-
cated that a phase I trial was a better choice than no treatment at
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Table 4 Patients' comprehension of the basic features of a phase trial
n (%)
understood the information was given about a phase trial
Completely 3 (10)
Almost completely 22 (71)
Unsure 4 (13)
Not very well 2 (6)
Not at all 0 (0)
understood the information my doctor gave me
Very well 6 (20)
Well 22 (73)
Not sure 1 (3)
Not very well 1 (3)
Not at all 0 (0)
The phase trial is an investigational treatment
Agree 31 (100)
Disagree 0 (0)
The effect of the new agent used in the phase trial is unknown
Agree 30 (97)
Disagree 1 (3)
It is unclear whether or not the phase trial will benefit me
Agree 29 (94)
Disagree 2 (6)
think that the side-effects of the drug used in the phase trial are
None or a little 0 (0)
Moderate 12 (38)
Severe 16 (50)
Life-threatening 3 (9)
don't know 1 (3)
The purpose of phase I trials isa
To observe the side-effects 7 (23)
To determine the tolerated/recommended dose 13 (43)
To screening for anti-tumour activity 2 (7)
To observe the response 12 (40)
To observe the survival 0
aAlthough patients were instructed to select the single most important reason,
some patients selected more than one reason.
all, and 16(50%) indicated that they decided to participate on the
advice ofor because oftheir trust in their physician. Furthermore,
six patients (19%) were motivated in their decision to participate
by the possibility of therapeutic benefit for themselves. Altruistic
reasons were given by only two patients (6%) as the primary
reason for participating, although most patients (90%) considered
that the phase I trials would help future cancer patients.
Although arriving at the decision to participate in the phase I
trial was easy for many patients (63%), only two patients made the
decision independently without consulting with family members,
friends or physicians (Table 3).
Comprehension
The patients' comprehension of the basic features of the phase I
trial is shown in Table 4. Most of the patients indicated that they
understood all (10%) or almost all (71%) of the information
provided about the trial in which they would participate, and 93%
indicated that they could understand the explanation given by their
doctors. Most patients comprehended the basic nature of a phase I
trial ofanti-cancer agents in that it is an investigation of a drug of
unknown effect and of unclear benefit to the patients themselves.
Nineteen patients (59%) anticipated that they might suffer severe
Table 5 Patients' expectations for the phase trial
n (%)
think there is no better choice than for the phase trial
Agree 13 (42)
Disagree 6 (19)
Don't know 12 (39)
have thought that would not receive any chemotherapy
Agree 15 (50)
Disagree 15 (50)
The phase trial (check as many as apply)
Will cure my cancer for certain 6 (19)
Will probably cure my cancer 6 (19)
Won't cure my cancer, but will survive for a long time 5 (16)
Won't cure my cancer, but might survive for a while 3 (9)
Might be ineffective, but I would like to try it anyway 11 (34)
Is a better choice than no treatment 5 (16)
predict that
Will be cured for certain 5 (16)
Will probably be cured 6 (19)
Will not be cured but will survive for a long time 8 (26)
Will not be cured but might survive for a while 8 (26)
Will not be cured and might not survive 4 (13)
Table 6 General issues of informed consent
n (%)
am free to withdraw from the phase trial at any time
True 30 (97)
False 1 (3)
can choose any treatment option
True 23 (88)
False 3 (12)
(50%) or life-threatening (9%) side-effects if they participated in
the phase I trial. All patients anticipated some side-effects. Almost
half of the patients were able to indicate accurately that the
purpose ofthe phase I trial in which they were scheduled to partic-
ipate was a dose-determination study. However, 12 patients (40%)
considered that the purpose of the phase I trial was to observe the
response. The accurate identification of the purpose of the phase I
trial was not correlated with the education level. Two of nine
(22%) patients who had a college-level or higher education indi-
cated the purpose ofthe phase I trial, as opposed to 11 of20 (55%)
educated to high school level or below. Similarly, the frequency of
the correct response was not correlated with age (more than or less
than 60 years) or with gender.
Expectations
Thirteen patients (42%) agreed that there was no better choice than
the phase I trial. To consider the option of no chemotherapy was
not correlated with age (more than or less than 60years) orgender.
Eleven patients (34%) indicated that they wanted to participate
even if the phase I trial turmed out to be ineffective. About one-
third of the patients (35%) considered that their cancer would be
cured. Moreover, 12 expected to be cured in thephase I trial (Table
5). Six of 13 (46%) patients who were older than 60 years indi-
cated that they considered their cancer curable, as opposed to 5 of
18 (28%) of those younger than 60 years. Whether a patient
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considered his or her cancer curable or incurable was not corre-
lated with age to a statistically significant degree.
General conditions of informed consent
The general conditions of informed consent, which included the
right to withdraw from the trial and the right to therapeutic choice,
were comprehended by most patients (Table 6).
DISCUSSION
Informed consent by participating patients is a fundamental
concept in any clinical study butespecially in phase I clinical trials
of anti-cancer agents, because there exist some ethical impedi-
ments in these trials (Ratain et al, 1993; Kodish et al, 1992). These
trials represent the first application of the given agent in human
subjects; moreover, in addition to the unknown toxicities as well
as uncertain effects, any benefits to the patient are uncertain. Thus,
participants must receive very thorough and precise information
conceming the trial's objectives, methods and potential risks, and
even conceming the potential future benefit of the study (Tobias
and Houghton, 1994).
The results of our survey show that all patients were aware of
taking part in a clinical research project and almost all understood
that risks were unknown and benefits uncertain. Moreover, more
than half anticipated the possibility of severe side-effects through
theirparticipation. Therefore, most patients thoroughly understood
the major issues of phase I trials after being informed of the
potential risks and benefits of the treatment. The possibility of
treatment-related risks and side-effects are well recognized after
informed consent is given even by patients in phase II1III studies
(Penman et al, 1984). It should be emphasized that these results
are in accord with those found in a study in the United States
(Daugherty et al, 1995). Almost all patients in our institution
seemed to have understood the voluntary nature ofparticipation in
phase I trials. However, abouthalfdid not appearto understand the
purpose of phase I trials completely, with 23% indicating that the
purpose was to observe side-effects. This could be regarded as an
insufficient rather than an erroneous answer, as the questions in
our study were multiple choice. The statement 'screening for anti-
tumour activity' was added as a possible response for the purpose
of phase I trials, because screening of anti-tumour activity is
thought to be a secondary end point ofphase I studies. It might be
difficult to conclude this answer as unsuitable as screening for
anti-tumour activity may be a part of such studies. For example,
PSC 833 is targeted to the patients who are potentially resistant to
vinca alkaloids oranthracyclines with multidrug resistance (MDR)
overexpression. The result of our study, in which about half of
patients did not appear to understand the purpose ofphase I trials
completely, seems similar to the result reported by Daugherty et al
(1995) who asked both open-ended and closed questions
(Daugherty et al, 1995). While it is absolutely essential that
patients understand the purpose as well as the details of the
method and possible risks and benefits of the clinical trials,
patients who have incurable cancer may not be receptive to infor-
mation on the theoretical basis of clinical trials and they are
focused more on how these will affect them, not the scientific
methodology. In other words, all patients in this study were aware
that they were participating in clinical research and almost all
understood the major issues ofaphase I trial, such as the unknown
risks and uncertain benefits, but they may nevertheless have
tended to be concemed about the details ofmethod, possible risks
and their own benefit rather than theoretical purposes. In general,
patients who understand the basic concepts ofthe treatment tend to
be younger and better educated (Daugherty et al, 1995; Cassileth
et al, 1980; Lavelle-Jones et al, 1993). However, in our study,
accurate identification of the purpose of a phase I trial did not
correlate with educational level and age. Unexpectedly, one-third
of our patients thought that their cancer would be cured even
although they were given a careful and thorough explanation.
There were no statistically significant correlation with age with
regard to patients viewing their cancers as curable. Some of these
reasons might be the small sample size, the minimal variance in
age and education in the present sample and the homogenous
nature ofJapanese culture and society. The majority ofthepatients
even in phase 11/111 studies are aware of the seriousness of their
illness (Penman et al, 1984). Although the physician's expectation
might influence the patient's attitude (Emanuel, 1995), patients
might refuse to accept information they don't wish to hear.
Patients' denial of their disease status may understandably
obstruct their ability to comprehend information given.
Rodenhuis et al (1984) reported that halfof the patients studied
were motivated by the hope of improvement of their disease and
that 2 of 10 patients believed the treatment to have been effective
(Rodenhuis etal, 1984). In ourstudy, however, only aboutone-fifth
ofthe patients were motivated toparticipate becausetheyperceived
that the treatment would be of benefit to them. Twenty patients
(63%) indicated the response of 'no treatment benefit to myselfbut
wish to participate anyway'. This response may not provide an
answer to the question ofwhy patients participated in these studies
but suggests that patients wished to try something rather than to do
nothing against their cancer. Furthermore, 11 patients (34%) indi-
cated the response of 'The phase I trial might be ineffective, but I
would like to try it anyway' in the expectation item. The reason for
this discrepancy is unknown. On the otherhand, halfofthepatients
believed or anticipated that participation in the phase I trial would
result in cure oftheir cancer or theirlong-term survival. Therefore,
patients may overestimate the benefits of a phase I trial or the
patients may be uncertain as to their actual feelings. These contra-
dictory responses suggest the delicate and complex mental state of
the patients, in that they are probably aware that their advanced
cancer is incurable but they nevertheless hope to be cured or to
survive for a long time. It is difficult to evaluate the quality of the
informed consent process, and Tomamichel et al (1995) have used
excellent methodologies for such an evaluation.
Patients are certainly aware that clinical studies can generally
help future cancerpatients, but altruistic feelings play alimited role
inmotivatingpatients toparticipate inphase I trials. Fromthis point
ofview, we share the opinion ofDaugherty et al (1995). Halfofthe
patients in our study indicated that they participated on the advice
of or because of trust in their physician. Twelve patients named
oncologists in our group as among those whose advice they sought
in making the decision to participate. This would suggest that the
relationship between our patients and physicians includes a satis-
factory level of trust. The level of trust in the patient-physician
relationship is one of the most important factors in conducting a
phase I trial (Daugherty et al, 1995). Thus, physicians have a great
responsibility in the informed consent process and must implement
stringent informed consent policies in conducting a clinical trial.
Three of ten patients had been urged to participate by their spouses
in the study by Rodenhuis et al (1984), but no patients in our study
cited family advice as the primary reason forparticipation.
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There is inter-institutional variation in opinions and practices
regarding patient selection, including that in the USA (Mick et al,
1994). There seem to be various methods and approaches based on
cultural and individual considerations (Willems and Sessa, 1989)
in the manner of informing cancer patients about phase I trials.
Although much more information is being disclosed to cancer
patients than in the past, there is still considerable disagreement
and regional differences in Japan about how much information
should be conveyed. Although many cancer patients are kept
unaware oftheir diagnosis and treatment, decisions are made rela-
tively independently by their physicians and family members in
general hospitals in Japan (Fukaura et al, 1995), almost all patients
who consult physicians in cancer centres are aware oftheir cancer.
In addition, clinical studies in Japan have been improved because
ofthe introduction ofthe Japanese guidelines for the methodology
of clinical evaluation of antineoplastic drugs (Suemasu et al,
1991). Therefore, it should be kept in mind that the conclusions of
this survey cannot be considered to be representative of Japan in
general but represent a highly selected population treated in our
institution. The results nevertheless suggest that there are no great
differences between patients' motivation, comprehension and
expectations in phase I trials in our institution and those in Western
countries if patients have good levels of information concerning
the intent and design ofthe trials.
We concluded that most patients in phase I trials conducted in
our institution were very well informed and made the decision to
participate freely. However, about half of the patients did not
appear to understand the purpose of the phase I trials completely,
and one-third ofthe patients did not appear to understand that their
disease was incurable.
This survey study is the first study concerning the informed
consent process in phase I trials. Our survey indicates that methods
for more clearly explaining the purpose ofclinical trials should be
developed. It may be difficult to improve the comprehension ofthe
purpose of phase I trials. The endeavour to promote the spread of
general concepts of a clinical trial of cancer chemotherapy would
necessitate innovations regarding existing conditions in Japan and
international standardization in clinical development of new anti-
cancer agents between Japan and the USA or Europe.
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APPENDIX: QUESTIONNAIRE ABOUT PHASE I
CLINICAL TRIALS
Please co-operate in the study that investigates people who are
taking part in phase I trials ofanti-cancer agents.
I understand you have given informed consent to participate in
the phase I trials. May I ask you questions? You may skip the ques-
tions that you are unwilling to answer. Your answers are confiden-
tial and certainly won't affect your treatment in any way.
Please return yourquestionnaire forms by mail or hand delivery,
ifyou willingly consent to the study.
1. My diagnosis is (as definitely as possible)
2. About the previous treatment
I have had some treatments...1
I have had no treatment...2
If treated
I have received (please mark all that apply)
Operation....
Chemotherapy... .2
Radiotherapy.. .3
Others... .4
I have been treated in (please mark all that apply)
National Cancer Center Hospital (NCCH). ..1
NCCH East...2
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other Cancer Center Hospital...3
University hospital...4
General Hospital...5
Others...6
I was satisfied with the previous treatment
Very well...1
Well....2
Not sure...3
Not very well...4
Not at all...5
3. About my disease, I predict that I
Will be cured for certain...1
Will probably be cured...2
Will not be cured, but will survive for long time...3
Will not be cured but might survive for a while...4
Will not be cured and might not survive...5
(Others)....6
4. I understood the information I was given about a phase I trial
(please select a single answer)
Completely...I
Almost completely...2
Unsure....3
Not very well...4
Not at all...5
5. I understood the information my doctor gave me
Very well...I
Well....2
Not sure...3
Not very well...4
Not at all...5
6. The purpose ofphase I trials is (please select the single most
important purpose)
To observe the side effects...I
To determine the tolerated/recommended dose...2
To screening for antitumour activity...3
To observe the response...4
To observe the survival...5
Others...6
I don't know...7
7. Concerning the concept ofcancer chemotherapy and the new
agent in phase I trial
A. A standard treatment of a cancer is the treatment with
evidence ofsurvival benefit or the most effective therapy for
the cancer. I think that there is a standard treatment for my
cancer
Agree...I
Disagree....2
Don't know...3
B. Ifthere is no standard treatment or ifit has failed to treat the
cancer, an investigational treatment or standard comfort care
should be chosen after consultation with the patient
I know...l
I don't know...2
C. The effect ofthe new agent used in the phase I trial is
unknown
Agree... I
Disagree....2
D. I think that the side-effects ofthe drug used in the phase I
trial are (please select a single answer)
None or a little... .
Moderate.. .2
Severe....3
Life-threatening....4
I don't know...5
E. The phase I trial is an investigational treatment
Agree... 1
Disagree...2
F. It is unclear whether or not the phase I trial will benefit me
Agree...I
Disagree...2
G. I think the phase I trial will help future cancer patients
Agree...1
Disagree...2
Don't know...3
H. I think there is no better choice than for the phase I trial
Agree...1
Disagree....2
Don't know...3
I. I have thought that I would not receive any chemotherapy
Agree... I
Disagree...2
J. I am free to withdraw from the phase I trial at any time
True...1
False.. .2
K. I can choose any treatment option
True... 1
False....2
L. Arriving at the decision to participate in the phase I trial was
Easy...I
Somewhat difficult...2
Very difficult...3
M. Who made the decision forparticipation in the phase I trial?
I made an independent decision... I
I consulted my (please mark all that apply)
Parent.. .2
Child.. .3
Sibling.. .4
Spouse.. .5
Other relative...6
Friend....7
Doctor here at the NCCH East.. .8
Doctor elsewhere...9
Nurse here at the NCCH East...10
Nurse elsewhere... 11
Others....12
N. Ifmy doctorproposed a phase I trial again, I would
Participate...I
Refuse....2
8A. The major reason forparticipation in the phase I trial is
(please select the single most important reason)
Some treatment benefit for myself...I
No treatment benefit to myselfbut wish to participate,
anyway....2
Family's advice...3
To help future cancer patients...4
Better option than no treatment...5
Advice ofdoctor...5
Trust in doctor...6
Others...7
B. The phase I trial
Will cure my cancer for certain... 1
Will probably cure my cancer...2
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Won't cure my cancer, but I will survive for a long
time....3
Won't cure my cancer but I might survive for a while...4
Is a better choice than no treatment...5
Others....5
9. At last, a few factual questions about you
How old are you? (years)
Gender (Male, Female)
What is your occupation?
Are you married?
Yes...1
No...2
Do you have a child?
Yes...1
No...2
What is the highest grade in school?
Primary school on the old system.. 1
Middle school on the old system...2
High school on the old system...3
Junior high school...4
High school...5
Junior college...6
College/post-graduate school...7
Thank you very much for your participation. Do you have any
questions about the study? Please mail the questionnaire or hand
it to a doctor/nurse, ifyou willingly consent to the study.
Thank you again.
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